Novo Nordisk A/S, headquartered in Denmark (DK), is a global leader in the pharmaceutical industry, specialising in diabetes care, obesity management, and hormone replacement therapies. Founded in 1923, the company has achieved significant milestones, including the development of innovative insulin products and GLP-1 receptor agonists that have transformed diabetes treatment. With a strong presence in Europe, North America, and Asia, Novo Nordisk is renowned for its commitment to sustainability and patient-centric solutions. Its core products, such as insulin pens and diabetes management devices, are distinguished by their advanced technology and user-friendly design. As a pioneer in diabetes care, Novo Nordisk holds a prominent market position, consistently recognised for its contributions to improving patient outcomes and advancing healthcare globally.
How does Novo Nordisk A Slash S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Novo Nordisk A Slash S's score of 86 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Novo Nordisk A/S reported total carbon emissions of approximately 3,831,000,000 kg CO2e. This figure includes 78,000,000 kg CO2e from Scope 1 emissions, 15,000,000 kg CO2e from Scope 2 emissions, and a significant 1,743,000,000 kg CO2e from Scope 3 emissions. The company has set ambitious climate commitments, aiming for net-zero emissions across its entire value chain by 2045. To achieve these goals, Novo Nordisk has established several key reduction targets. By 2030, the company aims to reduce its Scope 1 and 2 emissions by 100% from a 2018 base year. Additionally, it has committed to reducing its Scope 3 emissions by 33% by 2033, compared to a 2024 base year. This includes emissions from purchased goods and services, capital goods, and transportation. Novo Nordisk's long-term strategy includes maintaining a minimum of 100% reduction in Scope 1 and 2 emissions from 2030 through 2045, while also targeting a 90% reduction in Scope 3 emissions by 2045. These initiatives reflect the company's commitment to sustainability and its alignment with industry standards for greenhouse gas reduction.
Access structured emissions data, company-specific emission factors, and source documents
2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|
Scope 1 | 86,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 75,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 145,000,000 | 00,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novo Nordisk A Slash S is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.